Findings

What do systematic reviews say?

8 questions · 10 findings · 6 reviews · Childhood Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 60%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 30%Moderate 1 · 10%High 0 · 0%

Dexrazoxane vs no cardioprotective intervention

Progression‐free survival · children with cancer receiving anthracyclines

The review found no eligible studies for this question.

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation vs conventional chemotherapy plus whole lung irradiation

Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hyperfractionated radiotherapy vs radiotherapy

Progression‐free survival · children and young adults with diffuse brainstem glioma

The review found no eligible studies for this question.

1 finding from 1 review

Radiotherapy for diffuse brainstem glioma in children and young adults 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypofractionated radiotherapy vs radiotherapy

Progression‐free survival · children and young adults with diffuse brainstem glioma

Hypofractionated radiotherapy showed no clear difference in progression‐free survival compared with conventional radiotherapy (low certainty).

1 finding from 1 review

Radiotherapy for diffuse brainstem glioma in children and young adults 2016 · Cochrane Headline outcomes only
HR 1.19 [0.63, 2.22]
1 study · 71 participants
Low

Dinutuximab‐containing immunotherapy vs usual care

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rapid COJEC vs standard induction therapies

Progression‐free survival ‐ not reported · patients with high‐risk neuroblastoma

The review found no eligible studies for this question.

1 finding from 1 review

Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dexrazoxane vs no cardioprotective intervention or placebo

Progression‐free survival · adults with cancer receiving anthracyclines

Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).

3 findings from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.62 [0.43, 0.9]
1 study · 164 participants
Low
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 0.95 [0.64, 1.4]
1 study · 1 participants
Low
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
HR 1.18 [0.97, 1.43]
2 studies · 2 participants
Moderate